Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPS/Enzon Merger Provides Additional Leverage In Search For Preos Partner

Executive Summary

The NPS/Enzon $1.6 bil. merger deal provides more leverage to the companies' search for a partner for the osteoporosis treatment Preos

You may also be interested in...



Amgen Expects Cinacalcet Phase IIIb Trials To Increase Physician Awareness

Amgen is trying to increase physician awareness of the hyperparathyroidism agent cinacalcet prior to launch by conducting Phase IIIb studies, Exec VP-Global Commercial Operations George Morrow said

Amgen Expects Cinacalcet Phase IIIb Trials To Increase Physician Awareness

Amgen is trying to increase physician awareness of the hyperparathyroidism agent cinacalcet prior to launch by conducting Phase IIIb studies, Exec VP-Global Commercial Operations George Morrow said

Dendreon/Corvas Deal Follows 2003 Merger Theme: Biotech Cash Has Caché

Dendreon is adding a second R&D campus at essentially no cost via the proposed acquisition of Corvas

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel